Search results for "Oxygen therapy"
Recurrent primary spontaneous pneumothorax
A patient with HIV presented with chest tightness and lightheadedness.
https://acphospitalist.acponline.org/archives/2023/09/13/free/recurrent-primary-spontaneous-pneumothorax.htm
13 Sep 2023
Severity criteria for categorizing COPD exacerbations validated as prognostic tool
Patients with an exacerbation of chronic obstructive pulmonary disease (COPD) that was severe according to the recently proposed Rome criteria had about twice the risk of death within a year as those whose exacerbation was mild, a retrospective study found.
https://acphospitalist.acponline.org/archives/2023/08/02/severity-criteria-for-categorizing-copd-exacerbations-validated-as-prognostic-tool.htm
2 Aug 2023
Noninvasive ventilation options appear to offer benefits over standard oxygen, review finds
Compared to standard oxygen therapy for patients with acute hypoxic respiratory failure, continuous positive airway pressure by helmet probably reduces mortality and high-flow nasal cannula probably reduces the need for invasive mechanical ventilation, according to moderate-certainty evidence.
https://acphospitalist.acponline.org/archives/2023/04/26/noninvasive-ventilation-options-appear-to-offer-benefits-over-standard-oxygen-review-finds.htm
26 Apr 2023
Oxygenation by helmet, high flow didn't affect mortality in COVID-19, studies find
One trial randomized patients to helmet noninvasive ventilation or usual forms of respiratory support and found no differences. Another comparing high-flow and standard oxygen found a decrease in intubation rate with the former, but no change in any other outcome.
https://acphospitalist.acponline.org/archives/2022/09/28/free/oxygenation-by-helmet-high-flow-didnt-affect-mortality-in-covid-19.htm
28 Sep 2022
Latest COVID-19 research looks at plasma antigen levels, oral antivirals, HAIs
Studies found that plasma antigen levels of SARS-CoV-2 were associated with severity of illness, molnupiravir and nirmatrelvir-ritonavir improved outcomes in inpatients with mild-to-moderate illness, and small hospitals were hit hard by a pandemic rise in hospital-acquired infections (HAIs).
https://acphospitalist.acponline.org/archives/2022/08/31/free/latest-covid-19-research-looks-at-plasma-antigen-levels-oral-antivirals-hais.htm
31 Aug 2022
Research on CPAP, HFNO, IVIG, and lung transplants for COVID-19
One study found that continuous positive airway pressure (CPAP) outperformed conventional oxygen, but high-flow nasal oxygen (HFNO) did not. Another found no benefit from hyperimmune IV immunoglobulin (IVIG) in hospitalized patients. Two analyses showed good outcomes from lung transplants in COVID-19 patients.
https://acphospitalist.acponline.org/archives/2022/02/02/free/research-on-cpap-hfno-ivig-and-lung-transplants.htm
2 Feb 2022
NIH guidelines on anticoagulation in COVID-19; research on statin use, omicron variant
The NIH updated its guidelines to address anticoagulation in COVID-19 inpatients, treatment with atorvastatin did not appear to improve outcomes in the ICU, and several studies looked at characteristics of omicron.
https://acphospitalist.acponline.org/archives/2022/01/12/free/nih-guidelines-on-anticoagulation-research-on-statins-and-COVID-19.htm
12 Jan 2022
COVID-19 guideline update from NIH, postdischarge anticoagulation, remdesivir effects
The latest news on inpatient COVID-19 care includes some changes to the NIH guidelines for COVID-19 treatment, as well as studies showing that rivaroxaban after discharge reduced clots and remdesivir helped inpatients on no or low-flow oxygen but not those who were sicker.
https://acphospitalist.acponline.org/weekly/archives/2021/12/22/1.htm
22 Dec 2021
Early high-flow oxygen reduced need for mechanical ventilation, sped recovery
About a third of hypoxemic patients with severe COVID-19 who were randomized to high-flow nasal oxygen in the ED or ICU were eventually intubated, compared to 51% of those who received conventional oxygen, a trial in Columbia found.
https://acphospitalist.acponline.org/weekly/archives/2021/12/08/1.htm
8 Dec 2021
Mixed results for remdesivir, negative results for canakinumab, and new vaccine information
Remdesivir appeared to be of benefit in one study but was associated with increased length of stay and no improvement in survival in another, an industry-funded trial found no benefit for canakinumab in severe COVID-19, and the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine.
https://acphospitalist.acponline.org/weekly/archives/2021/07/21/1.htm
21 Jul 2021